Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
516.69
-3.40 (-0.65%)
At close: Apr 28, 2026, 4:00 PM EDT
517.50
+0.81 (0.16%)
After-hours: Apr 28, 2026, 7:37 PM EDT
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Madrigal Pharmaceuticals stock have an average target of 674.45, with a low estimate of 529 and a high estimate of 964. The average target predicts an increase of 30.53% from the current stock price of 516.69.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 20, 2026.
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 8 | 8 | 8 | 6 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 14 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $570 → $529 | Hold | Maintains | $570 → $529 | +2.38% | Feb 20, 2026 |
| Barclays | Barclays | Buy Initiates $964 | Buy | Initiates | $964 | +86.57% | Jan 28, 2026 |
| Citizens | Citizens | Buy Maintains $527 → $745 | Buy | Maintains | $527 → $745 | +44.19% | Jan 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $540 → $900 | Buy | Maintains | $540 → $900 | +74.19% | Dec 19, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $560 → $670 | Strong Buy | Maintains | $560 → $670 | +29.67% | Dec 11, 2025 |
Financial Forecast
Revenue This Year
1.52B
from 958.40M
Increased by 58.39%
Revenue Next Year
2.26B
from 1.52B
Increased by 48.55%
EPS This Year
-5.29
from -12.85
EPS Next Year
12.03
from -5.29
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.7B | 2.8B | ||||||
| Avg | 1.5B | 2.3B | ||||||
| Low | 1.4B | 1.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 74.7% | 83.3% | ||||||
| Avg | 58.4% | 48.6% | ||||||
| Low | 44.8% | 24.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.64 | 20.11 | ||||||
| Avg | -5.29 | 12.03 | ||||||
| Low | -9.51 | 2.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.